GlassScriptPhysician profile
Michael I Hanzly
NPI 1023247921
$5,980.62
in general payments reported to CMS, 2019-2025
29 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $708 · 2021: $2,110 · 2022: $617 · 2023: $481 · 2024: $217 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.67 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,028.03 | 2020-2025 | |
| Neotract INC. | $807.29 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $689.37 | 2019-2024 | Aveed, Xiaflex, Edex |
| Astellas Pharma US INC | $487.19 | 2019-2025 | Xtandi |
| Calyxo, INC. | $245.19 | 2024-2025 | Cvac Aspiration System |
| Janssen Biotech, INC. | $197.67 | 2022-2023 | Erleada |
| Axonics, INC. | $187.21 | 2020-2022 | |
| Integra Lifesciences Corporation | $149.99 | 2022 | |
| Teleflex LLC | $149.99 | 2021-2025 | Urolift |
| Medtronic USA, INC. | $117.37 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $115.35 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $96.64 | 2023-2025 | Gemtesa, Orgovyx |
| Urovant Sciences INC | $80.65 | 2021-2022 | |
| Allergan, INC. | $76.25 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $75.66 | 2019-2025 | Adstiladrin |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $53.56 | 2019 | |
| Urogen Pharma, INC. | $52.84 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.12 | 2019-2025 | |
| Medtronic, INC. | $45.76 | 2021 | |
| Clarus Therapeutics INC. | $41.93 | 2021 | |
| Progenics Pharmaceuticals, INC. | $41.71 | 2023-2025 | Pylarify |
| Olympus America INC. | $36.30 | 2021-2022 | |
| Boston Scientific Corporation | $34.10 | 2019 | |
| Merck Sharp & Dohme LLC | $30.24 | 2025 | Keytruda, Welireg |
| Novo Nordisk INC | $24.09 | 2024 | Rivfloza |
| Telix Pharmaceuticals | $22.57 | 2025 | Illuccix |
| Civco Medical Instruments | $18.75 | 2025 | |
| Pfizer INC. | $15.21 | 2020 | |
| 180 Medical, INC. | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hanzly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.